CRED 8 Presentations

01/07/2024

EMA report on 5 year PRIME in 2022

• EMA published on 3 March 20202 a report evaluating 5 year PRIME from March 2016 (Start PRIME) – June 2021 • 18 medicines that had PRIME support were approved in the European Union (EU) of which 10 received a conditional MA • 7 were ATMP, 16 concern rare diseases • Positive conclusion (PRIME enables earlier availability of life changing medicines) plus recommendations for improvement NB: In December 2021 PRIME elegibility granted to the first academia-led development!

The Organisation for Professionals in Regulatory Affairs 57

57

• During the pandemic in 2020 and 2021: rolling reviews were introduced for e.g. assessment Covid-19 vaccines • Evaluation of advantages and disadvantages ongoing Rolling review (e.g. Covid vaccins)

The Organisation for Professionals in Regulatory Affairs 58

58